[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-372449-105":59,"doc-detail-372449-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","car-nk-a-splendid-strategy-for-cancer-especially-for-gynecologic-tumor-review-article","CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor - Review Article","","NK cells are innate lymphocytes that kill tumor cells without MHC restriction or prior sensitization. Biotechnology advances have enabled chimeric antigen receptor (CAR) engineering, allowing targeted elimination. CAR-NK cells show strong preclinical and clinical potential for hematologic malignancies, yet solid-tumor use remains limited. Gynecologic cancer management often relies on surgery, chemotherapy, and radiotherapy with side effects and inconsistent efficacy. CAR-NK therapy is presented as a safer alternative to CAR-T, addressing toxicity barriers and improving translational prospects.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-nk-a-splendid-strategy-for-cancer-especially-for-gynecologic-tumor-review-article/372449/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-nk-a-splendid-strategy-for-cancer-especially-for-gynecologic-tumor-review-article/372449.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"为什么CAR-NK细胞被认为比CAR-T更适合某些临床应用？","Question",{"text":113,"@type":114},"文中指出CAR-T在部分妇科肿瘤中的应用受严重副作用（如细胞因子释放综合征和移植物抗宿主病）限制，而CAR-NK细胞在临床应用中具有更好的安全性特征。","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"CAR-NK细胞的基本工程原理是什么？",{"text":118,"@type":114},"CAR-NK细胞通过将嵌合抗原受体（CAR）基因导入NK细胞获得。CAR通常由负责识别靶抗原的胞外结构域（常为scFv）以及负责细胞内信号转导的胞内信号区域组成。",{"name":120,"@type":111,"acceptedAnswer":121},"综述重点评估了哪些CAR-NK工程创新方向？",{"text":122,"@type":114},"结果部分提到的创新包括多靶点CAR设计、通过基因编辑增强持续性，以及相较CAR-T的“现成型（off-the-shelf）”CAR-NK细胞策略。","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},372449,1790241897,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Immunity, Inflammation and Disease  \nREVIEW ARTICLE   \nCAR‐NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor  \nYisen Cao1  | Liying Wang2,3,4 | Liang Wang3,4   \n1Fujian Medical University | 2Laboratory of Gynecologic Oncology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China | 3Fujian Key Laboratory of Women and Children's Critical Diseases Research, Fujian Maternity and Child Health Hospital (Fujian Women and Children's Hospital), Fuzhou, Fujian, China | 4Fujian Clinical Research Center for  \nGynecological Oncology, Fujian Maternity and Child Health Hospital (Fujian Obstetrics and Gynecology Hospital), Fuzhou, Fujian, China Correspondence: Liang Wang ([wangliang7012@mails.jlu.edu.cn](wangliang7012@mails.jlu.edu.cn))  \nReceived: 11 January 2025 | Revised: 11 April 2025 | Accepted: 22 May 2025  \nFunding: This study was supported by National Natural Science Foundation of China (82303734) and Fujian Medical University Training Program of Innovation and Entrepreneurship for Undergraduates (C2025072) .  \nKeywords: CAR‐NK cell | cell therapy | chimeric antigen receptor | gynecological cancers | solid tumor  \nABSTRACT  \nBackground: NK cells are a class of innate lymphocytes capable of nonspecifically killing tumor cells without MHC restriction or prior sensitization. Recent advancements in biotechnology, particularly the development ofchimeric antigen receptors (CAR) and related technologies, have enabled targeted tumor cell elimination. CAR endows NK cells with enhanced functionality, with the extracellular domains typically consisting of single‐chain variable fragments (scFv) for targeting specific antigens. CAR‐NK cells have shown excellent results in several preclinical studies and clinical trials for hematologic malignancies. However, their clinical application in the treatment of solid tumors is still insufficient. Current treatments for gynecological cancers primarily involve surgery, chemotherapy, and radiotherapy, all of which often present substantial side effects and variable efficacy. While CAR‐T cell therapy has shown effectiveness in certain gynecological tumors, its clinical application is hindered by severe side effects, such as Cytokine Release Syndrome (CRS) and Graft‐Versus‐Host Disease (GVHD) . CAR‐NK cell therapy offers improved safety profiles in clinical applications.  \nObjective: This review aims to systematically evaluate recent methodological innovations in CAR‐NK engineering and their translational potential in tumor‐targeted treatment, providing valuable insights for clinical trials and studies.  \nMethods: Electronic databases, including PubMed and Web of Science were searched for relevant literature. Keywords are as  \nfollows: CAR‐NK cell; Chimeric antigen receptor; Solid tumor; cell therapy; gynecological cancers.  \nResults: CAR‐NK engineering has innovations such as multi‐targeted CAR design, gene editing for enhanced persistence, and“off‐the‐shelf” CAR‐NK cells compared to CAR‐T cells.  \nConclusion: CAR‐NK cell therapy combines safety and anti‐tumor efficacy, particularly for gynecological cancers.  \n1 | Introduction  \nNatural killer (NK) cells, constituting 10%–15% of peripheral blood lymphocytes and defined by the surface markers CD3 − CD56 + , mediate innate immunity through their ability to  \nperform effective immune surveillance and eliminate cancer cells without antigen‐specific MHC restriction or prior sensitization. Approximately 90% of circulating NK cells are mature CD56dimCD16bright cells, primarily responsible for mediating cytotoxic immune responses. The remaining 10% are immature  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Author(s) . Immunity, Inflammation and Disease published by Joh","cbCaiiMo2W8DWLRP","https://ap.wps.com/l/cbCaiiMo2W8DWLRP","pdf",922246,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"为什么CAR-NK细胞被认为比CAR-T更适合某些临床应用？\",\"answer\":\"文中指出CAR-T在部分妇科肿瘤中的应用受严重副作用（如细胞因子释放综合征和移植物抗宿主病）限制，而CAR-NK细胞在临床应用中具有更好的安全性特征。\"},{\"question\":\"CAR-NK细胞的基本工程原理是什么？\",\"answer\":\"CAR-NK细胞通过将嵌合抗原受体（CAR）基因导入NK细胞获得。CAR通常由负责识别靶抗原的胞外结构域（常为scFv）以及负责细胞内信号转导的胞内信号区域组成。\"},{\"question\":\"综述重点评估了哪些CAR-NK工程创新方向？\",\"answer\":\"结果部分提到的创新包括多靶点CAR设计、通过基因编辑增强持续性，以及相较CAR-T的“现成型（off-the-shelf）”CAR-NK细胞策略。\"}]","CAR-NK, a Splendid Strategy for Cancer, Especially for Gynecologic Tumor - Review Article | PDF",1790194547,25]